Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Vance G Fowler, Helen W Boucher, G Ralph Corey...
https://pubmed.ncbi.nlm.nih.gov/16914701/Actively Recruiting
Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-09-09
300
Participants Needed
20
Research Sites
43 weeks
Total Duration
Researchers are evaluating two commonly used treatments, daptomycin and vancomycin, for patients with methicillin-resistant Staphylococcus aureus MRSA bloodstream infections. This open-label randomized controlled trial is a sub-study of the larger Staphylococcus aureus Network Adaptive Platform SNAP trial and aims to compare these therapies to understand their outcomes in treating MRSA bacteremia. Participants receive either daptomycin by injection at a dose decided by their treating clinician but no less than 6 mg per kg of body weight, or vancomycin by injection with dosing tailored to achieve specific blood levels based on local standards. Both treatments are given through injections, and participants are randomly assigned to one of these two groups. During the study, participants are monitored for outcomes including the desirability of their overall health status 90 days after enrollment, clinical failure, serious adverse events, death from any cause, infectious complications, and specific side effects like muscle inflammation and eosinophilic pneumonia. These outcomes are assessed within 90 days post-enrollment, with safety monitoring extending up to 42 days for certain side effects. The study involves regular assessments to evaluate these measures and ensure participant safety throughout the trial period.
CONDITIONS
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
L
Lina Petrella
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Todd C. Lee MD MPH FIDSA
Lead Sponsor
University of Melbourne
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days
Participants receive either daptomycin or vancomycin by injection at doses decided by their clinicians to treat MRSA bloodstream infection.
Regular visits during treatment for monitoring
Duration - Up to 90 days post enrollment
Participants are monitored for health outcomes, side effects, and complications up to 90 days after enrollment.
Assessments at specified intervals during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Vance G Fowler, Helen W Boucher, G Ralph Corey...
https://pubmed.ncbi.nlm.nih.gov/16914701/Guanxuanzi Zhang, Na Zhang, Juan Xu...
https://pubmed.ncbi.nlm.nih.gov/37543121/Todd C. Lee MD MPH FIDSA
Lead Sponsor
University of Melbourne
Collaborating Sponsor